Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 54Lung Neoplasms 22Neoplasms 4Neoplasm Metastasis 3Carcinoma 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage IB-IIIA Non-small Cell Lung Carcinoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Non Small Cell Lung Cancer Metastatic 1NSCLC 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma 1

Interventions

pembrolizumab 16Cisplatin 16Magnetic Resonance Spectroscopy 13Specimen Handling 12Carboplatin 11Paclitaxel 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8durvalumab 6Radiotherapy, Intensity-Modulated 6Pemetrexed 6Cetuximab 6cemiplimab 5Radiotherapy 5Radiation 5Nivolumab 5Biopsy 5Ipilimumab 4Fluorouracil 41-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 4(225)Ac-DOTA-c(RGDyK) 4poly ICLC 3osimertinib 3atezolizumab 3Taxes 3Oxaliplatin 3Docetaxel 3130-nm albumin-bound paclitaxel 3ipatasertib 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma × osimertinib × 90 days × Clear all
NCT06417814 2026-05-14

TROPION-Lung15

AstraZeneca

Phase 3 Recruiting
744 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03778229 2026-04-23

SAVANNAH

AstraZeneca

Phase 2 Active not recruiting
367 enrolled 32 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05261399 2026-04-06

SAFFRON

AstraZeneca

Phase 3 Active not recruiting
345 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡